Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer

https://www.facingourrisk.org/XRAY/PARP-inhibitor-ovarian-cancer-survival

Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1910962?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)

Questions To Ask Your Health Care Provider

I have finished my first-line treatment. Should I consider maintenance therapy?
What are my options for maintenance therapy after chemotherapy?
What type of side effects should I expect on a PARP inhibitor?

Open Clinical Trials

Studies looking at PARP inhibitors and similar agents for treating people with ovarian cancer can be found here.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.